Kymera Therapeutics (KYMR) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.62
- EPS estimate
- −$0.71
- EPS surprise
- +12.99%
- Revenue surprise
- +98.32%
- Revenue
- $65.0M
- Revenue estimate
- $32.8M
- Reported
- Aug 5, 2026
Kymera Therapeutics reported Q2 2026 results on August 5, 2026. The company posted a loss of $0.62 per share, narrower than the $0.71 loss expected, a 12.99% beat. Revenue was $65.0 million, nearly double the $32.8 million estimate. A year earlier, in Q2 2025, the loss was $0.95 per share on revenue of $11.5 million.
Kymera has reported a loss in every one of the 20 quarters in the table. Annual losses were $2.88 per share in 2022, $2.52 in 2023, $2.97 in 2024 and $3.68 in 2025. The first half of 2026 shows a combined loss of $1.33, smaller than the $1.77 of the same period in 2025. Revenue has been irregular, ranging from $2.8 million in Q3 2025 to $65.0 million in Q2 2026, the high in the table. Kymera beat the EPS estimate eight times and missed 12 times over the period.
Kymera reported its third quarter between October 31 and November 10 in each of the past five years. That points to early November 2026 for the Q3 2026 report, which will show whether revenue stays near recent levels.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.71 | −$0.62 | +12.99% | $65.0M | SEC |
| Q1 2026 | Apr 30, 2026 | −$0.88 | −$0.71 | +19.36% | $34.4M | SEC |
| Q4 2025 | Feb 26, 2026 | −$0.78 | −$0.97 | −23.77% | $2.9M | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.77 | −$0.94 | −22.13% | $2.8M | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.81 | −$0.95 | −17.28% | $11.5M | SEC |
| Q1 2025 | May 9, 2025 | −$0.91 | −$0.82 | +9.59% | $22.1M | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.77 | −$0.88 | −13.58% | $7.4M | SEC |
| Q3 2024 | Oct 31, 2024 | −$0.83 | −$0.82 | +1.48% | $3.7M | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.68 | −$0.58 | +14.87% | $25.6M | SEC |
| Q1 2024 | May 2, 2024 | −$0.72 | −$0.69 | +4.25% | $10.3M | SEC |
| Q4 2023 | Feb 22, 2024 | −$0.40 | −$0.25 | +38.04% | $47.9M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.64 | −$0.90 | −41.33% | $4.7M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.64 | −$0.67 | −5.41% | $16.5M | SEC |
| Q1 2023 | May 4, 2023 | −$0.68 | −$0.70 | −2.40% | $9.5M | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.63 | −$0.60 | +4.82% | $16.1M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.76 | −$0.79 | −3.97% | $9.6M | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.69 | −$0.78 | −13.55% | $11.5M | SEC |
| Q1 2022 | May 3, 2022 | −$0.67 | −$0.71 | −6.24% | $9.6M | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.47 | −$0.66 | −41.45% | $15.3M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.37 | −$0.56 | −52.42% | $20.3M | SEC |
Quarterly revenue
Frequently asked questions
When did Kymera Therapeutics (KYMR) last report earnings?
Kymera Therapeutics last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did KYMR beat earnings estimates?
Yes. Kymera Therapeutics reported EPS of −$0.62 for Q2 2026 against a −$0.71 estimate — a 12.99% beat.
How much revenue did KYMR report last quarter?
Kymera Therapeutics reported $65.0M in revenue for Q2 2026, against a consensus estimate of $32.8M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.